Adamas Pharmaceuticals, Inc. (ADMS) Receives Overweight Rating from Piper Jaffray Companies

Piper Jaffray Companies reissued their overweight rating on shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) in a research report report published on Wednesday. They currently have a $30.00 price objective on the specialty pharmaceutical company’s stock.

A number of other brokerages have also issued reports on ADMS. BidaskClub raised shares of Adamas Pharmaceuticals from a strong sell rating to a sell rating in a report on Wednesday, August 23rd. Mizuho reaffirmed a buy rating and issued a $26.00 target price on shares of Adamas Pharmaceuticals in a research report on Tuesday, September 5th. Noble Financial reaffirmed a buy rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, August 9th. Cowen and Company reaffirmed an outperform rating and issued a $45.00 target price on shares of Adamas Pharmaceuticals in a research report on Sunday, May 28th. Finally, JMP Securities reaffirmed an outperform rating and issued a $33.00 target price (up from $29.00) on shares of Adamas Pharmaceuticals in a research report on Friday, August 25th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. Adamas Pharmaceuticals presently has a consensus rating of Hold and a consensus target price of $36.67.

Adamas Pharmaceuticals (NASDAQ ADMS) traded down 0.23% during trading on Wednesday, reaching $21.32. 206,807 shares of the company traded hands. Adamas Pharmaceuticals has a 12-month low of $12.10 and a 12-month high of $23.84. The firm’s 50 day moving average price is $18.21 and its 200 day moving average price is $17.22. The firm’s market capitalization is $480.00 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.12). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.03 million. Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. Adamas Pharmaceuticals’s revenue was down 90.9% on a year-over-year basis. During the same period last year, the business earned ($0.78) EPS. Equities research analysts expect that Adamas Pharmaceuticals will post ($3.77) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Adamas Pharmaceuticals, Inc. (ADMS) Receives Overweight Rating from Piper Jaffray Companies” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://sportsperspectives.com/2017/09/21/adamas-pharmaceuticals-inc-adms-receives-overweight-rating-from-piper-jaffray-companies.html.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Adamas Pharmaceuticals by 10.3% during the 1st quarter. Vanguard Group Inc. now owns 716,419 shares of the specialty pharmaceutical company’s stock valued at $12,537,000 after acquiring an additional 66,825 shares during the period. Goldman Sachs Group Inc. lifted its position in Adamas Pharmaceuticals by 212.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 60,897 shares of the specialty pharmaceutical company’s stock valued at $1,066,000 after acquiring an additional 41,436 shares during the period. Emerald Advisers Inc. PA lifted its position in Adamas Pharmaceuticals by 2.7% during the 2nd quarter. Emerald Advisers Inc. PA now owns 532,727 shares of the specialty pharmaceutical company’s stock valued at $9,317,000 after acquiring an additional 14,042 shares during the period. Geode Capital Management LLC lifted its position in Adamas Pharmaceuticals by 4.9% during the 1st quarter. Geode Capital Management LLC now owns 125,793 shares of the specialty pharmaceutical company’s stock valued at $2,201,000 after acquiring an additional 5,920 shares during the period. Finally, Parametric Portfolio Associates LLC lifted its position in Adamas Pharmaceuticals by 153.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 111,788 shares of the specialty pharmaceutical company’s stock valued at $1,956,000 after acquiring an additional 67,654 shares during the period. 69.24% of the stock is owned by institutional investors.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply